Vaccine developer Codagenix Inc., leveraging biotech innovations from Stony Brook University, has secured an additional $25 million in funding, extending a previous $20 million round from January 2020. This new funding, bringing the total to $45 million, includes contributions from manufacturing partner Serum Institute of India Pvt. Ltd., alongside existing investors Euclidean Capital and Adjuvant Capital.
The fresh capital will drive phase 1 clinical trials for Codagenix’s CodaVax-RSV vaccine, targeting respiratory syncytial virus in young children, and its CodaVax-H1N1 influenza vaccine. Serum Institute of India joins the funding round, building on their collaboration in developing the CoviLiv COVID-19 vaccine.
Codagenix’s technology, developed by Dr. Eckard Wimmer at Stony Brook, uses synthetic biology to craft vaccines with live viruses that are harmless due to recoded genetic material. The company, located at Farmingdale State College’s Broad Hollow Bioscience Park and with additional facilities in Cambridge, Massachusetts, is also participating in a WHO study of CoviLiv, a nasal COVID-19 vaccine aimed at simplifying vaccine distribution in developing regions.
Read the full article on Newsday by Ken Schachter here: https://www.newsday.com/business/codagenix-serum-institute-stony-brook-university-vaccine-rsv-covid-19-v8jhimpu